{"id":"NCT01551056","sponsor":"Aciex Therapeutics, Inc.","briefTitle":"A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)","officialTitle":"A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of Cetirizine 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2012-06","completion":"2012-06","firstPosted":"2012-03-12","resultsPosted":"2017-10-03","lastUpdate":"2017-11-07"},"enrollment":91,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Allergic Conjunctivitis"],"interventions":[{"type":"DRUG","name":"AC-170 0.24%","otherNames":[]},{"type":"DRUG","name":"AC-170 0%","otherNames":[]}],"arms":[{"label":"AC-170 0.24%","type":"EXPERIMENTAL"},{"label":"AC-170 0%","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.","primaryOutcome":{"measure":"Ocular Itching at Duration of Action (16 Hours + 1 Hour Post-dose)","timeFrame":"3, 5, 7 minutes post-CAC","effectByArm":[{"arm":"AC-170 0.24%","deltaMin":1.71,"sd":0.886},{"arm":"AC-170 0%","deltaMin":2.34,"sd":0.72}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":46},"commonTop":["Conjunctival haemorrhage","Visual acuity reduced","Hordeolum","Nasopharyngitis","Oropharyngeal Pain"]}}